Current perspectives for treatment of breast cancer

Nabholtz J.-M., Gelmon K., Bontenbal M., Spielmann M., Catimel G., Conte P., Klaassen U., Namer M., Bonneterre J., Fumoleau P., Winograd B., Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer, Journal of Clinical Oncology, 14, 6, pp. 1858-1867, (1996)

Winer E., Berry D., Duggan D., Et al., Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer-results from CALGB 9342, ProcAm Soc Clin Oncol, 17, (1998)

Peretz T., Sulkes A., Chollet P., Et al., A multicenter, randomized study of two schedules of paclitaxel in patients with advanced breast cancer, Eur J Cancer, 31, (1995)

Mamounas E., Brown A., Smith R., Et al., Effect of Taxol duration of infusion in advanced breast cancer (ABC): Results from NSABP B-26 trial comparing 3-2 24-hour infusion of high-dose Taxol, Proc Am Soc Clin Oncol, 17, (1998)

Holmes F.A., Valero V., Walters R., Et al., Phase III trial of paclitaxel administered over a 3-hour or 96-hour for metastatic breast cancer (MBC), Proc Am Soc Clin Oncol, 15, (1996)

Holmes F.A., Valero V., Buzdar A.U., Et al., Final results: Randomized phase III trial of paclitaxel by 3-hour versus 96-hour infusion in patients with metastatic breast cancer (MBC), the long and short of it, Proc Am Soc Clin Oncol, 17, (1998)

Seidman A.D., Hochhauser D., Gollub M., Et al., 96-hour paclitaxel infusion after progression during short taxane exposure: A phase II pharmacokinefic and pharmacodynamic study in metastatic breast cancer, J. Clin Oncol, 14, pp. 1877-1884, (1996)

Nabholtz J.-M., Senn H.J., Bezwoda W.R., Melnychuk D., Deschenes L., Douma J., Vandenberg T.A., Rapoport B., Rosso R., Trillet-Lenoir V., Drbal J., Molino A., Nortier J.W.R., Richel D.J., Nagykalnai T., Siedlecki P., Wilking N., Genot J.Y., Hupperets P.S.G.J., Pannuti F., Skarlos D., Tomiak E.M., Murawsky M., Alakl M., Riva A., Aapro M., Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracyclin

Chan S., Ffiedrichs K., Noel D., Et al., A phase III study of Taxotere versus doxorubicin in patients with metastatic breast cancer (MBC) who have failed an alkylating-containing regimen, Breast Cancer Res Treatment, 46, (1997)

Fumoleau P., Chevallier B., Kerbrat P., Krakowski Y., Misset J.-L., Maugard-Louboutin C., Dieras V., Azli N., Bougon N., Riva A., Roche H., A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: Report of the Clinical Screening Group of the EORTC, Annals of Oncology, 7, 2, pp. 165-171, (1996)

Nabholtz J.-M., Gelmon K., Bontenbal M., Spielmann M., Catimel G., Conte P., Klaassen U., Namer M., Bonneterre J., Fumoleau P., Winograd B., Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer, Journal of Clinical Oncology, 14, 6, pp. 1858-1867, (1996)

Winer E., Berry D., Duggan D., Et al., Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer-results from CALGB 9342, ProcAm Soc Clin Oncol, 17, (1998)

Peretz T., Sulkes A., Chollet P., Et al., A multicenter, randomized study of two schedules of paclitaxel in patients with advanced breast cancer, Eur J Cancer, 31, (1995)

Mamounas E., Brown A., Smith R., Et al., Effect of Taxol duration of infusion in advanced breast cancer (ABC): Results from NSABP B-26 trial comparing 3-2 24-hour infusion of high-dose Taxol, Proc Am Soc Clin Oncol, 17, (1998)

Holmes F.A., Valero V., Walters R., Et al., Phase III trial of paclitaxel administered over a 3-hour or 96-hour for metastatic breast cancer (MBC), Proc Am Soc Clin Oncol, 15, (1996)

Holmes F.A., Valero V., Buzdar A.U., Et al., Final results: Randomized phase III trial of paclitaxel by 3-hour versus 96-hour infusion in patients with metastatic breast cancer (MBC), the long and short of it, Proc Am Soc Clin Oncol, 17, (1998)

Seidman A.D., Hochhauser D., Gollub M., Et al., 96-hour paclitaxel infusion after progression during short taxane exposure: A phase II pharmacokinefic and pharmacodynamic study in metastatic breast cancer, J. Clin Oncol, 14, pp. 1877-1884, (1996)

Nabholtz J.-M., Senn H.J., Bezwoda W.R., Melnychuk D., Deschenes L., Douma J., Vandenberg T.A., Rapoport B., Rosso R., Trillet-Lenoir V., Drbal J., Molino A., Nortier J.W.R., Richel D.J., Nagykalnai T., Siedlecki P., Wilking N., Genot J.Y., Hupperets P.S.G.J., Pannuti F., Skarlos D., Tomiak E.M., Murawsky M., Alakl M., Riva A., Aapro M., Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracyclin

Chan S., Ffiedrichs K., Noel D., Et al., A phase III study of Taxotere versus doxorubicin in patients with metastatic breast cancer (MBC) who have failed an alkylating-containing regimen, Breast Cancer Res Treatment, 46, (1997)

Fumoleau P., Chevallier B., Kerbrat P., Krakowski Y., Misset J.-L., Maugard-Louboutin C., Dieras V., Azli N., Bougon N., Riva A., Roche H., A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: Report of the Clinical Screening Group of the EORTC, Annals of Oncology, 7, 2, pp. 165-171, (1996)